How to Get Retatrutide in the US

The short answer for 2026

If you are trying to get retatrutide the way you might get semaglutide or tirzepatide — call a telehealth provider, get a script, have a pharmacy fill it — that path does not exist yet. Retatrutide is investigational. It is not FDA-approved for any use, and Eli Lilly, the company developing it, has not submitted it to the FDA for approval. There is no approved product, no label, no pharmacy stock, and no insurance coverage.

That makes “how to get retatrutide” a fundamentally different question from the other access guides on this site. For an approved drug like tirzepatide, “how to get it” is a comparison of channels — telehealth, in-person clinic, self-pay, insurance. For retatrutide in 2026, there is essentially one legitimate channel: a clinical trial. Everything else is either legally dubious or outright unsafe.

Note: This page describes legal and trial access routes only. It is current as of June 19, 2026 and the landscape is moving quickly — Lilly is reading out Phase 3 data through 2026, so verify the current status before acting on anything here.

What retatrutide is, briefly

Retatrutide (Lilly’s development code LY3437943) is a once-weekly injectable that activates three hormone receptors at once — GLP-1, GIP, and glucagon — which is why it’s often called a “triple agonist.” It’s the next step beyond tirzepatide’s dual GLP-1/GIP mechanism, and early data has drawn attention because the weight-loss numbers in trials have been unusually large. For the full picture of what it is and what the evidence shows, see what is retatrutide and retatrutide for weight loss.

What matters for access is its regulatory stage, not its promise. A drug can have spectacular trial results and still be years away from a pharmacy shelf.

The one legitimate route: clinical trials

The only way to legally and safely receive retatrutide in the US right now is as a participant in one of Lilly’s ongoing studies. The two main programs are TRIUMPH (obesity and related conditions) and TRANSCEND (type 2 diabetes and cardiometabolic outcomes). Through 2026 these programs have been reading out Phase 3 results across obesity, type 2 diabetes, knee osteoarthritis, sleep apnea, cardiovascular and kidney disease, and liver disease.

How trial access actually works

• Find active studies. ClinicalTrials.gov is the authoritative registry. Search “retatrutide” and filter for studies that are recruiting. Each listing shows the condition, location, sponsor, and contact details.
• Check eligibility. Trials have strict inclusion and exclusion criteria — diagnosis, BMI range, lab values, prior treatments, other health conditions. Most people who are simply curious about the drug won’t meet a given trial’s criteria.
• Contact the study site. Recruiting trials list a coordinator. They’ll screen you, explain the protocol, and walk through informed consent. You may be randomized to placebo rather than active drug — that’s how controlled trials work.
• It’s free and supervised. Participants don’t pay for the investigational drug, and they receive structured medical monitoring. That supervision is the entire point and the thing no gray-market route can replicate.

The catch: enrollment is selective and often closed. As Lilly’s pivotal trials complete, many studies are fully enrolled or wrapping up, so availability of open slots shrinks over time rather than grows.

Why the “compounded prescription” route doesn’t apply here

For several older peptides, the legitimate path runs through a licensed prescriber and a 503A compounding pharmacy. That framework does not extend to retatrutide, for two concrete reasons:

1. It’s not an approved drug. Compounding is a way to make a tailored version of a drug for a specific patient — it presupposes the drug exists in the approved system or its active ingredient is otherwise permitted. Retatrutide has no approval to anchor that.
2. It’s not on the 503A bulks list. The FDA maintains a list of bulk drug substances pharmacies may compound from. Retatrutide — a patented, novel, investigational Lilly molecule — is not on it. A legitimate compounding pharmacy has no lawful basis to source a bulk active ingredient and compound it.

This is different from the GLP-1 compounding story you may have read about. Semaglutide and tirzepatide had a compounding window tied to official drug shortages; that window has closed, and even at its peak it applied to approved drugs in shortage. Retatrutide was never in that situation — it has never been an approved drug, so there was never a lawful compounding lane to open or close. For how the prescription mechanics genuinely break down for this compound, see retatrutide prescription.

The gray-market trap

Search retatrutide and you’ll find vials sold as “research chemicals,” “for laboratory use only,” or “not for human consumption.” That labeling is a legal fig leaf. These products are:

• Unverified. No regulatory body has confirmed their identity, concentration, or purity. A vial labeled as a given strength may contain more, less, something degraded, or something else entirely.
• Unsupervised. There’s no prescriber, no screening, no monitoring for the side effects retatrutide can cause (it’s a potent metabolic drug with real gastrointestinal and other effects).
• Legally exposed. Importing or using unapproved injectable drugs sits in a gray-to-illegal zone, and the “research use” framing doesn’t make self-injection lawful or safe.

The site’s position is plain: putting an unregulated injectable of unknown content into your body, with no medical oversight, is the exact harm we won’t help with. The fact that the drug works in trials does not make an unverified copy of it safe. This is also why we don’t publish dosage protocols for it — a number applied to an unknown product is meaningless at best and dangerous at worst.

How the routes compare

For a drug like tirzepatide, comparing routes means weighing telehealth speed against clinic thoroughness against cost. For retatrutide in 2026, the honest comparison looks like this:

• Clinical trial — Legitimate and free, with full medical supervision. Downsides: hard to qualify for, may be placebo, often closed, and not something you control. This is the only route that’s both legal and safe.
• Compounded prescription — Not a real option. No approval and no 503A bulks listing means legitimate pharmacies can’t supply it. Any provider offering “compounded retatrutide” is operating outside the standard framework.
• Gray-market “research” vials — Fast and available, but unregulated, unverified, unsupervised, and legally exposed. The site advises against this without qualification.

There is no version of this comparison where a convenient, legal, supervised purchase exists today. That’s simply the stage retatrutide is at.

What to do if you want this drug

If retatrutide specifically is what you’re after, you have two reasonable paths:

• Wait for approval. If Lilly completes Phase 3 and files an NDA, FDA review typically runs around a year, putting realistic public availability in the 2027–2028 range. When it launches it will be a branded, prescribed product — and at that point the normal access guides will apply.
• Use an approved alternative now. If your goal is the outcome (weight loss, metabolic improvement) rather than this molecule in particular, the FDA-approved GLP-1 class drugs are available today through legitimate channels. See how to get semaglutide and how to get tirzepatide. A clinician can help you weigh those against waiting for retatrutide.

The broader rules that govern all of this — what’s approved, what’s compoundable, what’s gray market — are laid out in are peptides legal in the US? and the general how peptides get prescribed. Retatrutide is a clean illustration of the principle: legitimacy follows approval, and approval hasn’t happened yet.

The honest bottom line

You cannot, in June 2026, lawfully and safely buy retatrutide the way you’d fill an ordinary prescription. The drug is investigational, the compounding lane doesn’t apply, and the gray market is a genuine safety risk, not a shortcut. The single legitimate door is a clinical trial — selective, supervised, free, and increasingly hard to enter as the trials complete. For most people the practical choice is to either wait for the approved product or pursue an FDA-approved alternative with a clinician now. Anyone telling you there’s an easy, legal way to get retatrutide today is selling you something the regulatory facts don’t support.